Receptos Inc (RCPT.OQ)

RCPT.OQ on NASDAQ Stock Exchange Global Select Market

135.30USD
1:00pm EST
Price Change (% chg)

$5.83 (+4.50%)
Prev Close
$129.47
Open
$130.51
Day's High
$135.37
Day's Low
$127.25
Volume
398,298
Avg. Vol
186,236
52-wk High
$135.37
52-wk Low
$22.11

RCPT.OQ

Chart for RCPT.OQ

About

Receptos, Inc. (Receptos) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company’s product candidates span three specialty disease areas. The Company’s lead asset, RPC1063, is being developed as an oral therapy for the treatment of... (more)

Overall

Beta: --
Market Cap (Mil.): $4,078.22
Shares Outstanding (Mil.): 31.50
Dividend: --
Yield (%): --

Financials

  RCPT.OQ Industry Sector
P/E (TTM): -- 212.78 38.55
EPS (TTM): -4.10 -- --
ROI: -47.94 -2.36 17.25
ROE: -52.32 -3.67 18.17
Search Stocks

Receptos bowel disorder drug meets mid-stage trial goal

- Receptos Inc said its experimental ulcerative colitis drug met the main goal in a mid-stage trial, sending its shares up 30 percent.

27 Oct 2014

UPDATE 1-Receptos bowel disorder drug meets mid-stage trial goal

Oct 27 - Receptos Inc said its experimental ulcerative colitis drug met the main goal in a mid-stage trial, sending its shares up 30 percent.

27 Oct 2014

UPDATE 1-Receptos shares soar as lead drug meets main goal

June 10 - Shares of Receptos Inc jumped about 40 percent in early trading after the biotechnology company said its experimental drug to treat relapsing multiple sclerosis (MS) met the main goal in a mid-stage trial.

10 Jun 2014

REFILE-Receptos shares soar as lead drug meets main goal

June 10 - Shares of Receptos Inc jumped 32 percent in premarket trading after the biotechnology company said its experimental multiple sclerosis drug met the main goal in a mid-stage trial.

10 Jun 2014

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF93.50 +0.50
Merck KGaA (MRCG.DE) €63.00 -1.90
Mylan Inc (MYL.OQ) $58.61 -0.01
Actavis PLC (ACT.N) $270.61 +0.14
Allergan, Inc. (AGN.N) $213.89 -0.11
Biogen Idec Inc (BIIB.OQ) $307.69 +2.77
Celgene Corporation (CELG.OQ) $113.69 +1.08

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks